AU2016226103A1 - Uses of PTHrP analogue in reducing fracture risk - Google Patents

Uses of PTHrP analogue in reducing fracture risk Download PDF

Info

Publication number
AU2016226103A1
AU2016226103A1 AU2016226103A AU2016226103A AU2016226103A1 AU 2016226103 A1 AU2016226103 A1 AU 2016226103A1 AU 2016226103 A AU2016226103 A AU 2016226103A AU 2016226103 A AU2016226103 A AU 2016226103A AU 2016226103 A1 AU2016226103 A1 AU 2016226103A1
Authority
AU
Australia
Prior art keywords
abaloparatide
bmd
bone
teriparatide
treated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016226103A
Other languages
English (en)
Inventor
Gary Hattersley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Radius Health Inc
Original Assignee
Radius Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56849024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2016226103(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Radius Health Inc filed Critical Radius Health Inc
Publication of AU2016226103A1 publication Critical patent/AU2016226103A1/en
Priority to AU2020267182A priority Critical patent/AU2020267182A1/en
Priority to AU2024202952A priority patent/AU2024202952A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2016226103A 2015-03-03 2016-03-03 Uses of PTHrP analogue in reducing fracture risk Abandoned AU2016226103A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020267182A AU2020267182A1 (en) 2015-03-03 2020-11-10 Uses of PTHrP analogue in reducing fracture risk
AU2024202952A AU2024202952A1 (en) 2015-03-03 2024-05-03 Uses of PTHrP analogue in reducing fracture risk

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562127729P 2015-03-03 2015-03-03
US62/127,729 2015-03-03
US201562165841P 2015-05-22 2015-05-22
US62/165,841 2015-05-22
US201562201564P 2015-08-05 2015-08-05
US62/201,564 2015-08-05
US201562239733P 2015-10-09 2015-10-09
US62/239,733 2015-10-09
US201662278762P 2016-01-14 2016-01-14
US62/278,762 2016-01-14
PCT/US2016/020787 WO2016141250A1 (en) 2015-03-03 2016-03-03 USES OF PTHrP ANALOGUE IN REDUCING FRACTURE RISK

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020267182A Division AU2020267182A1 (en) 2015-03-03 2020-11-10 Uses of PTHrP analogue in reducing fracture risk

Publications (1)

Publication Number Publication Date
AU2016226103A1 true AU2016226103A1 (en) 2017-08-31

Family

ID=56849024

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016226103A Abandoned AU2016226103A1 (en) 2015-03-03 2016-03-03 Uses of PTHrP analogue in reducing fracture risk
AU2020267182A Abandoned AU2020267182A1 (en) 2015-03-03 2020-11-10 Uses of PTHrP analogue in reducing fracture risk
AU2024202952A Pending AU2024202952A1 (en) 2015-03-03 2024-05-03 Uses of PTHrP analogue in reducing fracture risk

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020267182A Abandoned AU2020267182A1 (en) 2015-03-03 2020-11-10 Uses of PTHrP analogue in reducing fracture risk
AU2024202952A Pending AU2024202952A1 (en) 2015-03-03 2024-05-03 Uses of PTHrP analogue in reducing fracture risk

Country Status (8)

Country Link
US (8) US20170065682A1 (enExample)
EP (2) EP4137147A3 (enExample)
JP (5) JP6755256B2 (enExample)
AU (3) AU2016226103A1 (enExample)
CA (1) CA2977812A1 (enExample)
DK (1) DK3265115T3 (enExample)
ES (1) ES2927067T3 (enExample)
WO (1) WO2016141250A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017253674B2 (en) 2016-04-18 2021-07-29 Kindeva Drug Delivery L.P. Formulations of abaloparatide, transdermal patches thereof, and uses thereof
CA3045458A1 (en) * 2016-11-30 2018-06-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
EP3796941A4 (en) 2018-05-30 2022-12-28 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
EP3908605A1 (en) * 2019-01-11 2021-11-17 Radius Health, Inc. Methods for detecting neutralizing antibodies to parathyroid hormone (pth) and parathyroid hormone-related peptide (pthrp) analog
WO2020166561A1 (ja) 2019-02-14 2020-08-20 富士フイルム株式会社 骨折リスク評価値取得装置及びその作動方法並びに骨折リスク評価値取得プログラム
CN114364327A (zh) * 2019-09-12 2022-04-15 雷迪厄斯健康公司 用阿巴帕肽改善脊柱融合的方法
CN112646042A (zh) * 2019-10-10 2021-04-13 陕西麦科奥特科技有限公司 活性多肽化合物
AU2022205801A1 (en) * 2021-01-05 2023-07-13 Radius Health, Inc. Treatment of long bone fractures with abaloparatide
EP4346878A1 (en) * 2021-05-25 2024-04-10 Radius Health, Inc. Treatment and prevention of osteoporosis in high body mass index individuals
WO2025032376A1 (en) * 2023-08-04 2025-02-13 Precise Biopharma Pvt Ltd A room temperature stable solution for injection of abaloparatide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
MXPA04006728A (es) * 2002-01-10 2005-08-19 Osteotrophin Llc Tratamiento de desordenes oseos con medicamentos anabolicos esqueleticos.
CA2621264A1 (en) * 2005-09-06 2007-11-15 Zelos Therapeutics, Inc. Parathyroid hormone analogues and methods of use
AR062522A1 (es) * 2006-08-25 2008-11-12 Ares Trading Sa Tratamiento de desordenes en cartilagos
US7803770B2 (en) * 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
JP5375611B2 (ja) * 2006-10-03 2013-12-25 ラジウス ヘルス，インコーポレイテッド 骨同化作用を有するタンパク質のための薬物送達方法
WO2010022176A1 (en) * 2008-08-19 2010-02-25 Ferring International Center S.A. Methods of treatment for skeletal conditons
US20130006217A1 (en) * 2011-04-22 2013-01-03 Gary Hattersley METHOD OF DRUG DELIVERY FOR PTH, PTHrP AND RELATED PEPTIDES
WO2014004465A1 (en) * 2012-06-25 2014-01-03 The Brigham And Women's Hospital, Inc. Targeted therapeutics
SI3359241T1 (sl) * 2015-10-09 2021-11-30 Radius Health, Inc. Formulacije PTHRP-analogov, transdermalni obliži le-teh in uporabe le-teh

Also Published As

Publication number Publication date
EP3265115A1 (en) 2018-01-10
JP2022075999A (ja) 2022-05-18
JP2018508530A (ja) 2018-03-29
CA2977812A1 (en) 2016-09-09
US20250195619A1 (en) 2025-06-19
WO2016141250A1 (en) 2016-09-09
US20200376088A1 (en) 2020-12-03
EP3265115B1 (en) 2022-06-22
US20220125887A1 (en) 2022-04-28
US20200061160A1 (en) 2020-02-27
US20230321199A1 (en) 2023-10-12
US20170368148A1 (en) 2017-12-28
EP4137147A3 (en) 2023-04-05
JP6755256B2 (ja) 2020-09-16
JP2020189884A (ja) 2020-11-26
AU2020267182A1 (en) 2020-12-03
AU2024202952A1 (en) 2024-05-23
JP2023129523A (ja) 2023-09-14
ES2927067T3 (es) 2022-11-02
DK3265115T3 (da) 2022-09-05
US20230381283A1 (en) 2023-11-30
JP2025100689A (ja) 2025-07-03
US20170065682A1 (en) 2017-03-09
JP7049412B2 (ja) 2022-04-06
EP4137147A2 (en) 2023-02-22
EP3265115A4 (en) 2019-05-22

Similar Documents

Publication Publication Date Title
US20250195619A1 (en) Uses of pthrp analogue in reducing fracture risk
CZ20004134A3 (cs) Léčivo pro snížení rizika vertebrální nebo nevertebrální zlomeniny kosti u člověka a rizika osteoporózy
Chew et al. Abaloparatide: recombinant human PTHrP (1–34) anabolic therapy for osteoporosis
JP2009508820A (ja) 副甲状腺ホルモンアナログおよび使用法
US20250387454A1 (en) Uses of pthrp analogue in reducing fracture risk
CA2383574A1 (en) Method for reducing the risk of cancer
HK40088026A (en) Uses of abaloparatide in reducing fracture risk
US20220378881A1 (en) Treatment and prevention of osteoporosis in high body mass index individuals
Kim et al. Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of receptor activator of nuclear factor kappa-B ligand inhibition
Cosman Teriparatide and abaloparatide treatment for osteoporosis
Tabacco et al. PTH and PTHrP analogs: Treatment of osteoporosis
Costa et al. Denosumab
Lim et al. Therapeutic Approaches to
ADAMI et al. Parathyroid hormone and
Mass et al. Current Issues in Osteoporosis Therapy

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted